+ MUSE Alert

In this Issue

Table of Contents

  1. Rewriting the End
  2. Gregory E. Kaebnick
  3. p. 2
  4. DOI: https://doi.org/10.1353/hcr.0.0158
  5. restricted access
  1. Benefits, Harms, and Motives in Clinical Research
  2. Nancy M. P. King
  3. p. 3
  4. DOI: https://doi.org/10.1353/hcr.0.0161
  5. restricted access
  1. Open to Interpretation
  2. Tim Thorstenson
  3. p. 4
  4. DOI: https://doi.org/10.1353/hcr.0.0163
  5. restricted access
  1. Raymond De Vries replies:
  2. Raymond De Vries III
  3. pp. 4-5
  4. DOI: https://doi.org/10.1353/hcr.0.0169
  5. restricted access
  1. To the Editor:
  2. J. John Edgerton III
  3. p. 5
  4. DOI: https://doi.org/10.1353/hcr.0.0170
  5. restricted access
  1. Martha Jacobs replies:
  2. Martha Jacobs
  3. p. 5
  4. DOI: https://doi.org/10.1353/hcr.0.0165
  5. restricted access
  1. The Real Me?
  2. Lois Shepherd
  3. pp. 5-6
  4. DOI: https://doi.org/10.1353/hcr.0.0166
  5. restricted access
  1. Daniel Brudney replies:
  2. Daniel Brudney
  3. p. 6
  4. DOI: https://doi.org/10.1353/hcr.0.0171
  5. restricted access
  1. Teaching Intubation with Cadavers: Generosity at a Time of Loss
  2. Mark R. Mercurio
  3. pp. 7-8
  4. DOI: https://doi.org/10.1353/hcr.0.0150
  5. restricted access
  1. Constitutional Flaw?
  2. Carl E. Schneider
  3. pp. 9-10
  4. DOI: https://doi.org/10.1353/hcr.0.0152
  5. restricted access
  1. Anonymous Phone Calls
  3. p. 11
  4. DOI: https://doi.org/10.1353/hcr.0.0154
  5. restricted access
  1. Commentary
  2. Paul J. Ford
  3. pp. 11-12
  4. DOI: https://doi.org/10.1353/hcr.0.0167
  5. restricted access
  1. Commentary
  2. Joseph P. DeMarco
  3. p. 12
  4. DOI: https://doi.org/10.1353/hcr.0.0168
  5. restricted access
  1. Is Marketing the Enemy of Pharmaceutical Innovation?
  2. Kalman Applbaum
  3. pp. 13-17
  4. DOI: https://doi.org/10.1353/hcr.0.0157
  5. restricted access
  1. Rx for the Pharmaceutical Industry: Call Your Doctors
  2. Elizabeth A. Kitsis
  3. pp. 18-21
  4. DOI: https://doi.org/10.1353/hcr.0.0160
  5. restricted access
  1. Plan B and the Doctrine of Double Effect
  2. Rebecca Stangl
  3. pp. 21-25
  4. DOI: https://doi.org/10.1353/hcr.0.0162
  5. restricted access
  1. The Ethics of Altruism in Clinical Research
  2. Lynn A. Jansen
  3. pp. 26-36
  4. DOI: https://doi.org/10.1353/hcr.0.0164
  5. restricted access
  1. Going to Meet Death: The Art of Dying in the Early Part of the Twenty-First Century
  2. John Hardwig
  3. pp. 37-45
  4. DOI: https://doi.org/10.1353/hcr.0.0151
  5. restricted access
  1. Enhancing Humans, Controlling Evolution
  2. Courtney S. Campbell
  3. pp. 46-47
  4. DOI: https://doi.org/10.1353/hcr.0.0153
  5. restricted access
  1. Contributors
  3. p. 48
  4. DOI: https://doi.org/10.1353/hcr.0.0156
  5. restricted access
  1. Field Notes
  2. Mary Crowley
  3. p. c2
  4. DOI: https://doi.org/10.1353/hcr.0.0155
  5. restricted access
  1. Mad Pride and the Medical Model
  2. Alison Jost
  3. p. c3
  4. DOI: https://doi.org/10.1353/hcr.0.0159
  5. restricted access